A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

NCT04028245 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Spartalizumab
DRUG: Canakinumab

Sponsor

Columbia University

Collaborators

[object Object]